SelectiVe Androgen Receptor Modulators
Journal of Medicinal Chemistry, 2007, Vol. 50, No. 16 3869
4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg. Med.
Chem. Lett. 1999, 9, 1003-08. (c) Van Oeveren, A.; Motamedi, M.;
Mani, N. S.; Marschke, K. B.; Lopez, F. J.; Schrader, W. T.; Negro-
Vilar, A.; Zhi, L. Discovery of 6-N,N-Bis(2,2,2-trifluoroethyl)amino-
4-trifluoromethylquinolin-2(1H)-one as a Novel Selective Androgen
Receptor Modulator. J. Med. Chem. 2006, 49, 6143-46.
(13) Miyakawa, M.; Oguro, N.; Hanada, K.; Furuya, K.; Yamanoto, N.
Preparation of novel tetrahydroquinoline derivatives as androgen
receptor agonists. PCT Int. Appl. WO 2004013104, 2004.
(14) Segal, S.; Narayana, R.; Dalton, J. T. Therapeutic potential of the
SARMs: revisiting the androgen receptor for drug discovery. Expert
Opin. InVest. Drugs 2006, 15, 377-387.
Supporting Information Available: X-ray crystallographic data
on (R)-13, results from elemental analysis or HPLC analysis for
all tested compounds, procedure and spectra data of substituted
anilines. This material is available free of charge via the Internet
References
(1) Liu, P. Y.; Swerdloff, R. S.; Veldhuis, J. D. The rationale, efficacy
and safety of androgen therapy in older men: Future research and
current practice recommendations. J. Clin. Endocrinol. Metab. 2004,
89, 4789-4796.
(15) Zhang, X.; Li, X.; Allan, G. F.; Sbriscia, T.; Linton, O.; Lundeen, S.
G.; Sui, Z. Serendipitous discovery of novel imidazolopyrazole
scaffold as selective androgen receptor modulators. Bioorg. Med.
Chem. Lett. 2007, 17, 439-443.
(2) (a) Chengalvala, M.; Oh, T.; Roy, A. K. Selective androgen receptor
modulators. Expert Opin. Ther. Pat. 2003, 13, 59-66. (b) Gao, W.;
Bohl, C. E.; Dalton, J. T. Chem. ReV. Chemistry and structural biology
of androgen receptor. 2005, 105, 3352-3370. (c) Chen, J.; Kim, J.;
Dalton, J. T. Discovery and therapeutic promise selective androgen
receptor modulators. Mol. InterVentions 2005, 5, 173-188. (d)
Basaria, S.; Wahlstrom, J. T.; Dobs, A. S. Clinical review 138:
Anabolic-androgenic steroid therapy in the treatment of chronic
diseases. J. Clin. Endocrinol. Metab. 2001, 86, 5108-5117. (e)
Shahidi, N. T. A review of the chemistry, biological action, and
clinical applications of anabolic-androgenic steroids. Clin. Ther. 2001,
23, 1355-1390.
(3) Allan, G.; Sui, Z. Selective Androgen Receptor Modulators. NURSA
(doi 10.1621/nrs.01009).
(4) Bhasin, S.; Bremner, W. J. Clinical review 85: emerging issues in
androgen replacement therapy. Clin. Endocrinol. Metab. 1997, 82,
3-8.
(5) (a) Labrie, F. Mechanism of action and pure antiandrogenic properties
of flutamide. Cancer 1993, 72, 3816-27. (b) Furr, B. J.; Valcaccia,
B.; Curry, B.; Woodburn, J. R.; Chesterson, G.; Tucker, H. ICI 176,-
334: a novel non-steroidal, peripherally selective antiandrogen. J.
Endocrinol. 1987, 113, R7-9. (c) Furr, B.J. The development of
Casodex (bicalutamide): preclinical studies. Eur. Urol. 1996, 29
(Suppl. 2), 83-95. (d) Kolvenbag, G. J.; Blackledge, G. R.
Worldwide activity and safety of bicalutamide: a summary review.
Urology 1996, 47 (Suppl. 1A), 70-79. (e) Dole, E. J.; Holdsworth,
M. T. Nilutamide: an antiandrogen for the treatment of prostate
cancer. Ann. Pharmacother. 1997, 31, 65-75.
(6) (a) Cosman, F.; Lindsay, R. Selective estrogen receptor modulators:
clinical spectrum. Endocr. ReV. 1999, 20, 418-434. (g) Katzenel-
lenbogen, J. A.; O’Malley, B. W.; Katzenellenbogen, B. S. Tripartite
steroid hormone receptor pharmacology: interaction with multiple
effector sites as a basis for the cell- and promoter-specific action of
these hormones. Mol. Endocrinol. 1996, 10, 119-131. (c) McDon-
nell, D. P.; Clemm, D. L.; Hermann, T.; Goldman, M. E.; Pike, J.
W. Analysis of estrogen receptor function in vitro reveals three
distinct classes of antiestrogens. Mol. Endocrinol. 1995, 9, 659-
669. (d) Baracat, E.; Haidar, M.; Lopez, F. J. Pickar J; Dey, M.;
Negro-Vilar, A. Estrogen activity and novel tissue selectivity of delta
8,9-dehydroestrone sulfate in postmenopausal women. J. Clin.
Endocrinol. Metab. 1999, 84, 2020-2027.
(7) (a) Negro-Vilar, A. Selective androgen receptor modulators
(SARMs): a novel approach to androgen therapy for the new
millennium. J. Clin. Endocrinol. Metab. 1999, 84, 3459-62. (b) Zhi,
L.; Martinborough, E. Selective androgen receptor modulators
(SARMs). Ann. Rep. Med. Chem. 2001, 36, 169-180.
(8) Lee, Y. F.; Shyr, C. R.; Thin, T. H.; Lin, W. J.; Chang, C.
Convergence of two repressors through heterodimer formation of
androgen receptor and testicular orphan receptor-4: a unique signaling
pathway in the steroid receptor superfamily. Proc. Natl. Acad. Sci.
U.S.A. 1999, 96, 14724-9.
(16) (a) Marhefka, C. A.; Gao, W.; Chung, K.; Kim, J.; He, Y.; Yin, D.;
Bohl, C.; Dalton, J. T.; Miller, D. D. Design synthesis, and biol.
characterization of metabolically stable selective androgen receptor
modulators. J. Med. Chem. 2004, 47, 993-998. (b) Zhang, X.; Li,
X.; Allan, G.; Musto, A.; Lundeen, S. G.; Sui, Z. Discovery of indole-
containing tetracycles as a new scaffold for androgen receptor ligands.
Bioorg. Med. Chem. Lett. 2006, 16, 3233-3237. (c) Zhang, X.; Li,
X.; Allan, G. F.; Sbriscia, T.; Linton, O.; Lundeen, S. G.; Sui, Z.
Synthesis and SAR of novel hydantoin derivatives as selective
androgen receptor modulators. Bioorg. Med. Chem. Lett. 2006, 16,
5763-5766. (d) Lanter, J. C.; Fiordeliso, J. J.; Allan, G. F.; Musto,
A.; Hahn, D.; Sui, Z. A bioisosteric approach to the discovery of
indole carbinol androgen receptor ligands. Bioorg. Med. Chem. Lett.
2006, 16, 5646-5649. (e) Lanter, J.; Fiordeliso, J. J.; Jiang, W.; Allan,
G. F.; Lai, M.; Hahn, D.; Lundeen, S. G.; Sui, Z. The discovery of
a potent orally efficacious indole androgen receptor antagonist
through in vivo screening. Bioorg. Med. Chem. Lett. 2007, 17, 123-
126. (f) Ng, R. A.; Guan, J.; Alford, V. C., Jr.; Lanter, J.; Allan, G.;
Sbriscia, T.; Linton, O.; Lundeen, S.; Sui, Z. Synthesis and SAR of
potent and selective androgen receptor antagonists: 5,6-dichloro-
benzimidazole derivatives. Bioorg. Med. Chem Lett. 2007, 17, 955-
958.
(17) Herschberger, L. G.; Shipley, E. G.; Meyer, R. K. Myotrophic activity
of 19-nortestosterone and other steroids determined by modified
levator ani muscle method. Proc. Soc. Exp. Biol. Med. 1953, 83,
175-80.
(18) (a) Varney, M. D.; Palmer, C. L.; Deal, J. G.; Webber, S.; Welsh,
K. M.; Bartlett, C. A.; Morse, C. A.; Smith, W. W.; Janson, C. A.
Synthesis and biological evaluation of novel 2,6-diaminobenz[cd]-
indole inhibitors of thymidylate synthase using the protein structure
as a guide. J. Med. Chem. 1995, 38, 1892-1893. (b) Kirkovsky, L.;
Mukherjee, A.; Yin, D.; Dalton, J. T.; Miller, D. D. Chiral
nonsteroidal affinity ligands for the androgen receptor. 1. Bicaluta-
mide analogues bearing electrophilic groups in the B aromatic ring.
J. Med. Chem. 2000, 43, 581-590. (c) Mukherjee, A.; Kirkovsky,
L.; Yao, X. T.; Yates, R. C.; Miller, D. D. Enantioselective binding
of Casodex to the androgen receptor. Xenobiotica 1996, 26, 117-
122.
(19) For Cos-7 whole cell binding assay, see: Hammann, L. G.; Higuchi,
R. I.; Zhi, L.; Edwards, J. D.; Wang, X.-N.; Marsckle, K.; Kong, J.
W.; Farmer, L. J.; Jones, T. K. Synthesis and biological activity of
a novel series of nonsteroidal, peripherally selective androgen receptor
antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J.
Med. Chem. 1998, 41, 623-639.
(20) For LNCap assay, see: Salvati, M. E.; Balog, A.; Pickering, D. A.;
Giese, S.; Fura, A.; Li, W.; Patel, R.; Hanson, R. L.; Mitt, T.;
Roberge, J.; Corte, J. R.; Spergel, S. H.; Rampulla, R. A.; Misra, R.;
Xiao, H.-Y. Preparation of fused succinimides as modulators of
nuclear hormone receptor function. PCT Int. Appl. WO 2003062241,
2003.
(21) Allan, G. F.; Tannenbaum, P.; Sbriscia, T.; Linton, O.; Lai, M.-T.;
Haynes-Johnson, D.; Bhattacharjee, S.; Zhang, X.; Sui, Z.; Lundeen,
S. G. A selective androgen receptor modulator with minimal prostate
hypertrophic activity enhances lean body mass in male rats and
stimulates sexual behavior in female rats. Endocrinology, submitted.
(22) Chen, B.-C.; Sundeen, J. E.; Zhao, R. Process for the preparation of
N-(substituted phenyl)-3-alkyl-, aryl- and heteroarylsulfonyl-2-hy-
droxy-2-alkyl- and haloalkylpropanamide antiandrogenic compounds.
PCT Int. Appl. WO 2002024638, 2002.
(9) (a) Gronemeyer, H.; Gustafsson, J. A.; Laudet, V. Principles for
modulation of the nuclear receptor superfamily. Nat. ReV. Drug
DiscoV. 2004, 3, 950-954. (b) Mooradian, A. D.; Morley, J. E.;
Korenman, S. G. Biological actions of androgens. Endocr. ReV. 1987,
8, 1-28.
(10) Dalton, J. T.; Mukherjee, A.; Zhu, Z.; Kirkovsky, L.; Miller, D. D.
Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Com-
mun. 1998, 244, 1-4.
(11) Hamann, L.G. Discovery and preclinical profile of a highly potent
and muscle selective androgen receptor modulator (SARM). Natl.
Meet. Am. Chem. Soc., Med. Chem. DiV. 2004, 227, MEDI-011.
(12) (a) Hamann, L. G.; Mani, N. S.; Davis, R. L.; Wang, X.-N.; Marschke,
K. B.; Jones, T. K. Discovery of a potent, orally active, nonsteroidal
androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluorom-
ethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J. Med. Chem. 1999,
42, 210-212. (b) Edwards, J. P.; Higuchi, R. I.; Winn, D. T.; Pooley,
C. L. F.; Caferro, T. R.; Marschke, K. B.; Hamann, L. G.; Zhi, L.;
Jones, T. K. Nonsteroidal androgen receptor agonists based on
(23) Tucker, H.; Crook, J. W.; Chesterson, G. J. Nonsteroidal antiandro-
gens. Synthesis and structure-activity relationships of 3-substituted
derivatives of 2-hydroxypropionanilides. J. Med. Chem. 1988, 31,
954-9.
JM0613976